The global Preimplantation Genetic Testing Market size is projected to amount to a value of USD 221.1
million by 2024, according to a new report by Grand View Research, Inc. The
market is primarily driven by an increase in number of offspring born with
inherited medical conditions. Thanks to the emergence of preimplantation
genetic testing (PGT) and diagnosis to detect nearly all genetically inherited
conditions, couples who are carriers of such conditions can screen their
embryos at an earlier stage.
Rising adoption of IVF, resulting from an increase in incidence of pregnancy-related complications, is projected to boost demand for preimplantation genetic testing services. Women undergoing IVF are expected to undergo PGT cycles in order to prevent the transfer of chromosomal abnormalities to their offspring.
Increasing demand for these tests can also be attributed to rising infertility rate around the world. This has been brought on by various environmental and lifestyle factors, eventually driving the need for PGT services.
Rising adoption of IVF, resulting from an increase in incidence of pregnancy-related complications, is projected to boost demand for preimplantation genetic testing services. Women undergoing IVF are expected to undergo PGT cycles in order to prevent the transfer of chromosomal abnormalities to their offspring.
Increasing demand for these tests can also be attributed to rising infertility rate around the world. This has been brought on by various environmental and lifestyle factors, eventually driving the need for PGT services.
Full Research Report On Preimplantation Genetic Testing Market Analysis:
http://www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market
http://www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market
Further Key Findings From the Study Suggest:
·
Preimplantation genetic testing
is available for different types of services, which include X-linked diseases,
Human Leukocyte Antigen (HLA) typing, chromosomal abnormalities, freeze embryo
testing, aneuploidy screening, detection of serious late-onset diseases, and gender
selection. Preimplantation genetic testing for chromosomal abnormalities
accounted for approximately 29% of the market share due to advancements in its
screening by the use of noninvasive prenatal testing, which employs cell-free
DNA for early detection of chromosomal abnormalities, such as Patau syndrome,
Edwards syndrome, and Down syndrome.
·
This technology has various
applications. Amongst all the applications, embryo HLA typing for stem cell
therapy dominated with a share of over 30%. This largest share can be
attributed to the benefits associated with the use of PGD for identification of
HLA compatible embryos for stem cell therapy.
·
Although usage of these tests
for inherited chromosomal disease is observed to have less penetration in the
current scenario, it is expected to witness tremendous growth in the coming
years due to increasing adoption rate of this service for detection of
inherited genomic anomalies, such as sickle cell anemia and Huntington’s
disease.
·
Europe accounted for the
largest share with respect to revenue as a result of growing awareness about
the scope of these diagnostic services for delivering genetically fit
offspring. Also, developed infrastructure, rising investments by governmental
bodies, and presence of key players in this region, collectively encourages
growth of this industry in this region.
·
Some of the key players that
have commercialized PGT services include F. Hoffmann-La Roche AG; Genea
Limited; Quest Diagnostics, Illumina, Inc.; Natera, Inc; CooperSurgical, Inc;
LabCorp; California Pacific Medical Center; Thermo Fisher Scientific, Inc;
Igenomix; Reproductive Genetic Innovations, LLC; CombiMatrix; Good Start
Genetics, Inc; Bioarray S.L; and Reproductive Health Science Ltd.
·
These key participants are
actively involved in the R&D initiatives for development of novel PGT
services. Partnership between entities and acquisition of small companies by
major companies in order to reinforce its status in the market as well as to
expand its product catalog for this vertical is expected boost revenue
generation in preimplantation genetic diagnostics.
·
For instance, In December 2015,
Natera, entered into a partnership with MedGenome, provider of genomic
solutions for personalized healthcare in India. As per this partnership,
MedGenome will be allowed to use the Panorama noninvasive prenatal test in its
research laboratory. As a result, MedGenome becomes the first provider of this
service in India.
View More Reports Of This Category By Grand View Research
At: https://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented
preimplantation genetic testing market on the basis of application, type, and
region:
Type Outlook (Market Revenue in USD Million, 2013
- 2024)
·
Chromosomal Abnormalities
·
X-linked Diseases
·
Freeze Embryo Testing
·
Aneuploidy Screening
·
HLA Typing
·
Other PGT Types
Application Outlook (Revenue in USD Million, 2013
- 2024)
·
Embryo HLA Typing for Stem Cell
Therapy
·
IVF Prognosis
·
Late-Onset Genetic Disorders
·
Inherited Genetic Disease
·
Others
Regional Outlook (Market Revenue in USD Million,
2013 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o UK
·
Asia Pacific
o Japan
o China
·
Latin America
o Brazil
o Mexico
·
Middle East and Africa
o South Africa
View Press
Release of this research report by Grand View Research: https://www.grandviewresearch.com/press-release/global-preimplantation-genetic-testing-pgt-market
About Grand
View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For More Information: www.grandviewresearch.com
For More Information: www.grandviewresearch.com